



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:
Jeffrey L. Browning et al.

Examiner: Not Assigned

Group Art Unit: 1642

Serial No.: 10/003,211

Filing Date: October 31, 2001

For: Soluble Lymphotoxin-Beta Receptors as Therapeutic Agents for
Treatment of Systemic Lupus Erythematosus (as amended)

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on:

July 3, 2002
Date

Jacqueline L. Marlier

COMMUNICATION TO CORRECT ERROR IN FILING RECEIPT

Box Missing Parts
Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Upon receipt of the Official Filing Receipt for the above-referenced application, a copy of which is attached, the applicant noticed that the PCT priority application number is incorrect.

The PCT application reads:

PCT/US97/19435


should read:

PCT/US97/19436

If any fee is required, authorization is hereby given to charge Deposit Account
No. 02-2327.

Respectfully submitted,

Date: July 3, 2002



Niki D. Cox, Esq.
Reg. No. 42, 446
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-2079 (Direct)
(617) 679-2838 (Facsimile)

10893

COPY OF PAPERS
ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 09 2002

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/003,211	10/31/2001	1642	740	A013 US CON	7	8	1

Niki D. Cox, Esq.
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142

JAN 10 2002

NDC

CONFIRMATION NO. 6970

FILING RECEIPT



OC0000000726848

Date Mailed: 01/04/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Jeffrey L. Browning, Brookline, MA;
Paula S. Hochman, Newton, MA;
Paul D. Rennert, Millis, MA;
Fabienne MacKay, Vaucluse, AUSTRALIA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/299,139 04/23/1999
WHICH CLAIMS BENEFIT OF 60/029,060 10/25/1996

Foreign Applications

PCT/US97/19436 10/24/1997

PCT/US97/19436

If Required, Foreign Filing License Granted 01/04/2002

Projected Publication Date: To Be Determined - pending completion of Corrected Papers

Non-Publication Request: No

Early Publication Request: No

Title

Soluble lymphotoxin beta receptor and anti-lymphotoxin receptor and ligand antibodies as



therapeutic agents for treatment

Preliminary Class

514

COPY OF PAPERS
ORIGINALLY FILED

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED


The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Docket No. A013USCON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:
Jeffrey L. Browning et al.

Examiner: Not Assigned

Group Art Unit: 1642

Serial No.: 10/003,211

Filing Date: October 31, 2001

For: Soluble Lymphotoxin-Beta Receptors as Therapeutic Agents for Treatment of Systemic Lupus Erythematosus (as amended)

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on:

July 3, 2002
Date

Jacqueline L. Marlier
Jacqueline L. Marlier

RESPONSE TO NOTICE TO FILE CORRECTED
APPLICATION PAPERS

In response to the Notice to File Corrected Application Papers of a Nonprovisional Application mailed January 4, 2002, Applicant hereby submits copy of notice and substitute drawings in compliance with 37 CFR 1.84.


No fee is deemed necessary in connection with the filing of this Response. However, in an abundance of caution, if any fee is required, authorization is hereby given to charge Deposit Account No. 02-2327.

Respectfully submitted,

Date: July 3, 2002

Niki D. Cox
Niki D. Cox, Esq.
Reg. No. 42, 446
BIOGEN, INC.
14 Cambridge Center
Cambridge, MA 02142
(617) 679-2079 (Direct)
(617) 679-2838 (Facsimile)

COPY OF PAPERS
ORIGINALLY FILED



COPY OF PAPERS
ORIGINALLY FILED

PTO/SB/17 (10-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$) 1,440

Complete if Known

Application Number	10/003,211
Filing Date	10/31/2001
First Named Inventor	Browning, Jeffrey
Examiner Name	TBD
Group Art Unit	1642
Attorney Docket No.	A013 US CON

METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number 02-2327
Deposit Account Name

☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17

☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	740	201	370	Utility filing fee	
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	

SUBTOTAL (1) (\$) 0

2. EXTRA CLAIM FEES

Total Claims -20** = X = 0
Independent Claims -3** = X = 0
Multiple Dependent = 0

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	1,440
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Petitions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	Submission of Information Disclosure Stmt	
581	40	581	40	Recording each patent assignment per property (times number of properties)	
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 1,440

SUBMITTED BY

Name (Print/Type) Niki D. Cox

Registration No. (Attorney/Agent)

42,446

Complete (if applicable)

Telephone (617) 679-2079

Signature

Niki D. Cox

Date

July 3, 2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#4



Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

BOX: Missing Parts

Assistant Commissioner for Patents
Washington, D.C. 20231

on July 3, 2002
Date

Signature

Jacqueline L. Marlier

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

1. Transmittal Form (1 pg.);
2. Fee Transmittal Form (1 pg.);
3. Response to Notice to File Corrected Application Papers 1 pg.);
4. Communication to Correct Error in Filing Receipt (2 pgs.);
5. Copy of Notice to File Corrected Application Papers (1 pg.);
6. Copy of marked-up Filing Receipt (2 pgs.);
7. 10 Sheets of Substitute Drawings;
8. Petition for a 4-Month Extension of Time (1 pg.);
9. Return Receipt Postcard

COPY OF PAPERS
ORIGINALY FILED